Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

SciClone IPOs on Hong Kong Exchange, Raising $279 Million

publication date: Mar 3, 2021

SciClone Pharma, a Shanghai in-licensing company, staged a Hong Kong IPO that raised $279 million. Previously listed in the US, SciClone was privatized in 2017 for $605 million. The IPO valued the company at $1.6 billion. SciClone plans to use the proceeds to in-license additional products and fund clinical development of its existing assets. Its major marketed product is Zadaxin^® (thymalfasin), an immune system adjuvant that is used to treat hepatitis B, though SciClone says it was also proved helpful for SARS and COVID-19. More details....

Stock Symbol: (HK: 6600)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.